研究单位：[1]Xintian Pharmaceutical[2]Beijing Tongren Hospital,Capital Medical University[3]The First Affiliated Hospital of Guangzhou Medical University[4]Peking University Shenzhen Hospital[5]The Central Hospital Of WUHAN[6]Wuhan No.1 Hospital
Objective: To evaluate the efficacy and safety of Ningmitai Capsules and Silodosin Capsules in the treatment of Benign Prostatic Hyperplasia (BPH) with Lower Urinary Tract Symptoms (LUTS) compared with Tamsulosin Hydrochloride Sustained Release Capsules.
Study design: A multicenter, prospective, randomized, double-blind, positive controlled clinical study.
